Novel assays to investigate the mechanisms of latent infection with HIV-2

被引:1
|
作者
Lu, Michael D. [1 ]
Telwatte, Sushama [1 ,2 ]
Kumar, Nitasha [1 ,2 ]
Ferreira, Fernanda [3 ]
Martin, Holly Anne [1 ,2 ]
Kadiyala, Gayatri Nikhila [1 ,2 ]
Wedrychowski, Adam [1 ,2 ]
Moron-Lopez, Sara [1 ,2 ]
Chen, Tsui-Hua [2 ]
Goecker, Erin A. [4 ]
Coombs, Robert W. [4 ]
Lu, Chuanyi M. [1 ,2 ]
Wong, Joseph K. [1 ,2 ]
Tsibris, Athe
Yukl, Steven A. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] San Francisco VA Hlth Care Syst, Dept Med, San Francisco, CA 94121 USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
来源
PLOS ONE | 2022年 / 17卷 / 04期
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; BLOOD MONONUCLEAR-CELLS; LONG TERMINAL REPEAT; PLASMA VIRAL LOAD; TYPE-2; SUBTYPE-A; PERIPHERAL-BLOOD; ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; GENE-EXPRESSION;
D O I
10.1371/journal.pone.0267402
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although there have been great advancements in the field of HIV treatment and prevention, there is no cure. There are two types of HIV: HIV-1 and HIV-2. In addition to genetic differences between the two types of HIV, HIV-2 infection causes a slower disease progression, and the rate of new HIV-2 infections has dramatically decreased since 2003. Like HIV-1, HIV-2 is capable of establishing latent infection in CD4(+) T cells, thereby allowing the virus to evade viral cytopathic effects and detection by the immune system. The mechanisms underlying HIV latency are not fully understood, rendering this a significant barrier to development of a cure. Using RT-ddPCR, we previously demonstrated that latent infection with HIV-1 may be due to blocks to HIV transcriptional elongation, distal transcription/polyadenylation, and multiple splicing. In this study, we describe the development of seven highly-specific RT-ddPCR assays for HIV-2 that can be applied to the study of HIV-2 infections and latency. We designed and validated seven assays targeting different HIV-2 RNA regions along the genome that can be used to measure the degree of progression through different blocks to HIV-2 transcription and splicing. Given that HIV-2 is vastly understudied relative to HIV-1 and that it can be considered a model of a less virulent infection, application of these assays to studies of HIV-2 latency may inform new therapies for HIV-2, HIV-1, and other retroviruses.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] HIV-2 Infection: Latest Advances
    Gunaratne, Shauna H.
    Gandhi, Rajesh T.
    CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2019, 11 (03) : 233 - 242
  • [2] Dolutegravir for the treatment of HIV-2 infection
    Trevino, Ana
    Cabezas, Teresa
    Belen Lozano, Ana
    Garcia-Delgado, Rosa
    Force, Luis
    Maria Fernandez-Montero, Jose
    de Mendoza, Carmen
    Caballero, Estrella
    Soriano, Vincent
    JOURNAL OF CLINICAL VIROLOGY, 2015, 64 : 12 - 15
  • [3] Antiretroviral treatment of HIV-2 infection
    de Mendoza, Carmen
    Requena, Silvia
    Caballero, Estrella
    Cabezas, Teresa
    Penaranda, Maria
    Jose Amengual, Maria
    Saez, Ana
    Belen Lozano, Ana
    Ramos, Jose M.
    Soriano, Vincent
    FUTURE VIROLOGY, 2017, 12 (08) : 461 - 472
  • [4] Are Confirmatory Assays Reliable for HIV-1/HIV-2 Infection Differentiation? A Multicenter Study
    Guiraud, Vincent
    Bocobza, Jonathan
    Desmonet, Marion
    Damond, Florence
    Plantier, Jean-Christophe
    Moreau, Ghislaine
    Wirden, Marc
    Stefic, Karl
    Barin, Francis
    Gautheret-Dejean, Agnes
    JOURNAL OF CLINICAL MICROBIOLOGY, 2023, 61 (08)
  • [5] Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions
    de Mendoza, Carmen
    Lozano, Ana B.
    Caballero, Estrella
    Cabezas, Teresa
    Ramos, Jose M.
    Soriano, Vicente
    AIDS REVIEWS, 2020, 22 (01) : 44 - 56
  • [6] HIV-2 Infection: Latest Advances
    Shauna H. Gunaratne
    Rajesh T. Gandhi
    Current Treatment Options in Infectious Diseases, 2019, 11 : 233 - 242
  • [7] HIV-2 infection: a call for controlled trials
    Matheron, Sophie
    AIDS, 2008, 22 (16) : 2073 - 2074
  • [8] HIV-2 Drug Resistance Genotyping from Dried Blood Spots
    Raugi, Dana N.
    Nixon, Robert S.
    Leong, Sally
    Faye, Khadim
    Diatta, Jean Phillipe
    Sall, Fatima
    Smith, Robert A.
    Sall, ElHadji Ibrahima
    Malomar, Jean Jacques
    Seydi, Moussa
    Gottlieb, Geoffrey S.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (01)
  • [9] Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants
    Smith, Robert A.
    Raugi, Dana N.
    Wu, Vincent H.
    Zavala, Christopher G.
    Song, Jennifer
    Diallo, Khardiata Mbaye
    Seydi, Moussa
    Gottlieb, Geoffrey S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [10] 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2
    Gottlieb, Geoffrey S.
    Raugi, Dana N.
    Smith, Robert A.
    LANCET HIV, 2018, 5 (07): : E390 - E399